NANOG and intrahepatic cholangiocarcinoma: To determine whether the CRISPR-Cas9-targeted and expanded (passage 31) NES-mScarlet hiPSCs retained their pluripotent properties, the expression of the pluripotency genes POU5F1 (OCT4), SOX2 and NANOG was determined in these cells by RT-qPCR (QC No. 1) and ICC.